Orexigen Therapeutics, Inc. has entered into a commercial supply agreement with Sanofi for the manufacture of Contrave (32 mg naltrexone sustained release (SR) / 360 mg bupropion SR) for territories outside North America. Sanofi will manufacture Contrave tablets at one of several facilities in France.   “We are pleased to engage a manufacturer with Sanofi’s scale and expertise,” said Michael Narachi, chief executive officer of Orexigen. “This agreement expands and diversi...